Beatriz Llombart1, Carlos Monteagudo2, Onofre Sanmartín3, José Antonio López-Guerrero4, Carlos Serra-Guillén3, Andrés Poveda5, Esperanza Jorda6, Antonio Fernandez-Serra4, Antonio Pellín2, Carlos Guillén3, Antonio Llombart-Bosch2. 1. Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain; Department of Pathology, Hospital Clínico Universitario, Valencia, Spain. Electronic address: beatriz.llombart@uv.es. 2. Department of Pathology, Hospital Clínico Universitario, Valencia, Spain. 3. Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain. 4. Department of Molecular Biology, Instituto Valenciano de Oncología, Valencia, Spain. 5. Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. 6. Department of Dermatology, Hospital Clínico Universitario, Valencia, Spain.
Abstract
BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is an uncommon cutaneous tumor, usually low grade, except for the fibrosarcomatous variant (DFSP-FS). OBJECTIVES: We sought to compare the clinicopathological, immunohistochemical, genetic, and therapeutic features between DFSP and DFSP-FS. METHODS: The clinicopathological features were reviewed in 63 DFSP and 12 DFSP-FS. Immunohistochemistry and multiplex reverse transcriptase-polymerase chain reaction were carried out using formalin-fixed, paraffin-embedded tissue, using specific primers for collagen type I alpha 1 (COL1A1) and platelet-derived growth factor beta (PDGFB). RESULTS: DFSP-FS was associated with tumor history longer than 5 years (P = .009), tumor size greater than 4 cm (P = .001), more stages of modified Mohs micrographic surgery (P = .005), expansive subcutaneous infiltration (P = .005), muscular invasion (P = .0001), absence of CD34 staining (P = .018), p53 positivity (P = .006), and increased proliferative activity (P = .004) compared with DFSP. The COL1A1-PDGFB fusion transcript was found in 100% DFSP-FS and 72% DFSP. No association was found between the different COL1A1-PDGFB fusion transcripts and the different histologic subtypes. Wide local excision (2 cm) was performed in 47% of cases and modified Mohs micrographic surgery in 53%. After a mean follow-up of 73 months (range 21-235), 6 patients had local recurrence (5 DFSP, 1 DFSP-FS) and one died of disease (DFSP-FS). The only factor related to local recurrence was the type of surgery (17% wide local excision vs 0% modified Mohs micrographic surgery) (P = .006). LIMITATIONS: Our study is retrospective. Prospective studies are necessary to confirm our results. CONCLUSIONS: DFSP-FS reflects tumor progression in DFSP, with larger size, particular invasive patterns, p53 expression, and increased proliferative activity. However, as in low-grade DFSP, appropriate surgery permits a tumor-free excision. COL1A1-PDGFB is a useful tool for diagnosis of DFSP and particularly for DFSP-FS.
BACKGROUND:Dermatofibrosarcoma protuberans (DFSP) is an uncommon cutaneous tumor, usually low grade, except for the fibrosarcomatous variant (DFSP-FS). OBJECTIVES: We sought to compare the clinicopathological, immunohistochemical, genetic, and therapeutic features between DFSP and DFSP-FS. METHODS: The clinicopathological features were reviewed in 63 DFSP and 12 DFSP-FS. Immunohistochemistry and multiplex reverse transcriptase-polymerase chain reaction were carried out using formalin-fixed, paraffin-embedded tissue, using specific primers for collagen type I alpha 1 (COL1A1) and platelet-derived growth factor beta (PDGFB). RESULTS:DFSP-FS was associated with tumor history longer than 5 years (P = .009), tumor size greater than 4 cm (P = .001), more stages of modified Mohs micrographic surgery (P = .005), expansive subcutaneous infiltration (P = .005), muscular invasion (P = .0001), absence of CD34 staining (P = .018), p53 positivity (P = .006), and increased proliferative activity (P = .004) compared with DFSP. The COL1A1-PDGFB fusion transcript was found in 100% DFSP-FS and 72% DFSP. No association was found between the different COL1A1-PDGFB fusion transcripts and the different histologic subtypes. Wide local excision (2 cm) was performed in 47% of cases and modified Mohs micrographic surgery in 53%. After a mean follow-up of 73 months (range 21-235), 6 patients had local recurrence (5 DFSP, 1 DFSP-FS) and one died of disease (DFSP-FS). The only factor related to local recurrence was the type of surgery (17% wide local excision vs 0% modified Mohs micrographic surgery) (P = .006). LIMITATIONS: Our study is retrospective. Prospective studies are necessary to confirm our results. CONCLUSIONS:DFSP-FS reflects tumor progression in DFSP, with larger size, particular invasive patterns, p53 expression, and increased proliferative activity. However, as in low-grade DFSP, appropriate surgery permits a tumor-free excision. COL1A1-PDGFB is a useful tool for diagnosis of DFSP and particularly for DFSP-FS.
Authors: Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez Journal: Mol Cancer Ther Date: 2015-04-07 Impact factor: 6.261
Authors: Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée Journal: Mod Pathol Date: 2016-03-18 Impact factor: 7.842
Authors: Dennis A Wicherts; Frits van Coevorden; Houke M Klomp; Martine A van Huizum; J Martijn Kerst; Rick L M Haas; Hester H van Boven; J A van der Hage Journal: World J Surg Oncol Date: 2013-03-08 Impact factor: 2.754